• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Zeitgemäße Farbkommunikation mit dem VITA Easyshade V

, Medizintechnik, Vita Zahnfabrik H. Rauter GmbH & Co. KG

Die VITA Easyshade-Technologie für die digitale Zahnfarbbestimmung hat sich seit über 10 Jahren in Zahnarztpraxis und Labor etabliert. Um jetzt...

IT-Sicherheit in Kliniken

, Medizintechnik, Adiccon GmbH

Auf den Einsatz moderner Informationstechnolo­gie kann in keiner Klinik mehr verzichtet werden. Die zahlreichen IT-Werkzeuge unterstützen alle...

Shifting the focus to process and quality control and risk management

, Medizintechnik, Messe Erfurt GmbH

In fields from orthopaedics to implantology and dental technology, the huge amount of design and manufacturing freedom provided by Additive Manufacturing...

Disclaimer